Royalty Pharma (RPRX) reported Q4 net income Tuesday of $208 million, down from $494 million a year earlier.
Comparable analyst estimates were not available.
Total income and other revenues ended Dec. 31 were $594 million, down from $596 million a year earlier.
Analysts surveyed by FactSet expected $687 million.
As of Dec. 31, the company said it had $929 million in cash and cash equivalents.
Shares of the UK biopharmaceutical company were up more than 2% in Tuesday's premarket activity.
Price: 32.45, Change: +0.73, Percent Change: +2.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。